Birth Weight, Gestational Age, and Risk of Pediatric-Onset MASLD
In this nationwide study of young individuals with biopsy-proven MASLD, low birth weight and SGA were associated with development of MASLD and progressive liver disease, suggesting a need for structured screening measures to diagnose these conditions early in high-risk individuals.
Authors
- Jiangwei Sun (ORCID: https://orcid.org/0000-0003-2252-684X)
- David Bergman (ORCID: https://orcid.org/0000-0003-4808-1762)
- Hannes Hagström (ORCID: https://orcid.org/0000-0002-8474-1759)
- Fahim Ebrahimi (ORCID: https://orcid.org/0000-0001-5862-966X)
- Jialu Yao (ORCID: https://orcid.org/0000-0001-9047-6712)
- Olof Stephansson (ORCID: https://orcid.org/0000-0003-1528-4563)
- Jonas F. Ludvigsson
- Jonas Söderling (ORCID: https://orcid.org/0000-0001-9006-2835)
Institutions
- Karolinska University Hospital (SE)
- University Hospital of Basel (CH)
- Karolinska Institutet (SE)
- Örebro University Hospital (SE)
- Columbia University (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.32420
- Citations
- 13
- Primary Topic
- Birth, Development, and Health
- Type
- article
- Field-Weighted Citation Impact
- 14.42
Funders
- National Science Foundation
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Gilead Sciences
- GW Pharmaceuticals
- Kowa Company
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Novo Nordisk